"The results of ASCOT-LLA were first presented and simultaneously published online in the Lancet in 2003 [2]. As reported by heartwire ,
lipid lowering with atorvastatin resulted in a significant 36% reduction in the primary end point of fatal coronary heart disease and nonfatal MI after a median follow-up of 3.3 years. At the time the study was stopped, there was a nonsignificant trend toward reduction in all-cause mortality. Upon completion of ASCOT-LLA, investigators continued to collect mortality data and evaluated the mortality outcomes in participants originally randomized to atorvastatin or placebo in the ASCOT-LLA arm for a median of 11 years.
At the end of the extended follow-up, all-cause mortality was significantly reduced by 14% (hazard ratio
0.86; 95% CI 0.76–0.98),
and noncardiovascular mortality was significantly reduced by 15% (HR 0.85; 95% CI 0.73–0.99). There was no difference in death from cardiovascular causes."Δηλαδή, όπως το καταλαβαίνω εγώ τουλάχιστον, μέχρι τα 3,3 πρώτα χρόνια χρήσης ατορβαστατίνης έχουμε μια μείωση των θανάτων κατά 36%, δηλαδή κατά 1/3 περίπου. Μετά τα 11 χρόνια όμως η γενική θνησιμότητα (απ' όλες τις αιτίες μειώθηκε κατά 14%) ενώ στους θανάτους από καρδιαγγειακά αίτια δεν υπήρχε καμία διαφορά.
Αποστολέας